Contact

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve preclinical/clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market.

Jan Nilsson

Karin Agerman

Peter Ekolind

Louise Aspenberg

Annika Ericsson

Pernilla Fagergren

Alvar Grönberg

Martin Linhult

Birgitta Ståhl

Esbjörn Melin

Daniela Morath

About CombiGene AB

Follow what's happening at CombiGene, subscribe to our newsletter.